Breast Cancer 15-307

February 08, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: 15-307

Feasibility study of adjuvant enzalutamide for the treatment of early stage AR(+) triple negative breast cancer.

Who’s eligible: Patient must have Stage 1, 2 or 3 invasive breast cancer, Triple negative, and AR(+), defined as ≥ 1% nuclear staining by IHC testing. Neo/adjuvant chemotherapy is permitted, but not required. At least 4 weeks from end of surgery, chemotherapy, or radiotherapy with resolution of any toxicity to Grade 1 or less. Must be within 6 months of completion of therapy (including radiation therapy)

This study is for women age 18 and older.

Available at: Backus Hospital, MidState Medical Center, The Hospital of Central Connecticut, Hartford Hospital.